Last reviewed · How we verify

Paxlovid (Copackaged) — Competitive Intelligence Brief

Paxlovid (Copackaged) (Nirmatrelvir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral protease inhibitor. Area: Infectious Disease.

marketed Antiviral protease inhibitor SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Paxlovid (Copackaged) (Nirmatrelvir) — Pfizer. Nirmatrelvir inhibits SARS-CoV-2 main protease; ritonavir inhibits CYP3A-mediated metabolism of nirmatrelvir.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Paxlovid (Copackaged) TARGET Nirmatrelvir Pfizer marketed Antiviral protease inhibitor SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease) 2023-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Antiviral protease inhibitor class)

  1. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paxlovid (Copackaged) — Competitive Intelligence Brief. https://druglandscape.com/ci/paxlovid-copackaged. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: